Cargando…

Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects

Renal cancer management is challenging from diagnosis to treatment and follow-up. In cases of small renal masses and cystic lesions the differential diagnosis of benign or malignant tissues has potential pitfalls when imaging or even renal biopsy is applied. The recent artificial intelligence, imagi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferro, Matteo, Musi, Gennaro, Marchioni, Michele, Maggi, Martina, Veccia, Alessandro, Del Giudice, Francesco, Barone, Biagio, Crocetto, Felice, Lasorsa, Francesco, Antonelli, Alessandro, Schips, Luigi, Autorino, Riccardo, Busetto, Gian Maria, Terracciano, Daniela, Lucarelli, Giuseppe, Tataru, Octavian Sabin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003020/ https://www.ncbi.nlm.nih.gov/pubmed/36902045 http://dx.doi.org/10.3390/ijms24054615

Ejemplares similares

Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization
por: Ferro, Matteo, et al.
Publicado: (2021)

Artificial intelligence and radiomics in evaluation of kidney lesions: a comprehensive literature review
por: Ferro, Matteo, et al.
Publicado: (2023)

Molecular Imaging Diagnosis of Renal Cancer Using (99m)Tc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques
por: Tataru, Octavian Sabin, et al.
Publicado: (2023)

Radiomics in prostate cancer: an up-to-date review
por: Ferro, Matteo, et al.
Publicado: (2022)

Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement
por: Ferro, Matteo, et al.
Publicado: (2023)

Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma
por: Lasorsa, Francesco, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
por: Lasorsa, Francesco, et al.
Publicado: (2023)

Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy
por: Ferro, Matteo, et al.
Publicado: (2022)

Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer
por: Lasorsa, Francesco, et al.
Publicado: (2023)

The Efficacy of Flogofilm(®) in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
por: Barone, Biagio, et al.
Publicado: (2023)

The Impact of Meat Intake on Bladder Cancer Incidence: Is It Really a Relevant Risk?
por: Aveta, Achille, et al.
Publicado: (2022)

Cancer Stem Cells in Renal Cell Carcinoma: Origins and Biomarkers
por: Lasorsa, Francesco, et al.
Publicado: (2023)

Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer
por: di Meo, Nicola Antonio, et al.
Publicado: (2022)

Beyond PSA: The Role of Prostate Health Index (phi)
por: Ferro, Matteo, et al.
Publicado: (2020)

Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer
por: Ferro, Matteo, et al.
Publicado: (2021)

Radiotherapy to the Primary Tumor: The First Step of a Tailored Therapy in Metastatic Prostate Cancer
por: Ferro, Matteo, et al.
Publicado: (2022)

Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management—Current Trends and Future Perspectives
por: Tătaru, Octavian Sabin, et al.
Publicado: (2021)

Novel Key Ingredients in Urinary Tract Health—The Role of D-mannose, Chondroitin Sulphate, Hyaluronic Acid, and N-acetylcysteine in Urinary Tract Infections (Uroial PLUS(®))
por: Crocetto, Felice, et al.
Publicado: (2023)

Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
por: di Meo, Nicola Antonio, et al.
Publicado: (2022)

Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy
por: Ferro, Matteo, et al.
Publicado: (2021)

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis
por: Ferro, Matteo, et al.
Publicado: (2021)

Fascin-1 and its role as a serological marker in prostate cancer: a prospective case–control study
por: Tătaru, Octavian Sabin, et al.
Publicado: (2021)

Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer
por: Ferro, Matteo, et al.
Publicado: (2021)

The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis
por: Ferro, Matteo, et al.
Publicado: (2021)

Complement System and the Kidney: Its Role in Renal Diseases, Kidney Transplantation and Renal Cell Carcinoma
por: Lasorsa, Francesco, et al.
Publicado: (2023)

Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies
por: Sciarra, Alessandro, et al.
Publicado: (2021)

Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature
por: Monti, Martina, et al.
Publicado: (2022)

Lymphocyte to Monocyte Ratio: A New Independent Prognostic Factor in Bladder Cancer Progression?
por: Ferro, Matteo, et al.
Publicado: (2021)

BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored
por: Crocetto, Felice, et al.
Publicado: (2021)

Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies
por: Ferro, Matteo, et al.
Publicado: (2020)

Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence
por: Barone, Biagio, et al.
Publicado: (2023)

Liquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives
por: Crocetto, Felice, et al.
Publicado: (2022)

Quality of Life and Psychological Distress among Patients with Small Renal Masses
por: Vartolomei, Liliana, et al.
Publicado: (2022)

Surgical blood loss during holmium laser enucleation of the prostate (HoLEP) is not affected by short-term pretreatment with dutasteride: a double-blind placebo-controlled trial on prostate vascularity
por: Busetto, Gian Maria, et al.
Publicado: (2020)

Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)
por: Ferro, Matteo, et al.
Publicado: (2017)

Three-dimensional facial swelling evaluation of pre-operative single-dose of prednisone in third molar surgery: a split-mouth randomized controlled trial
por: Antonelli, Alessandro, et al.
Publicado: (2023)

Radiogenomics of lung cancer
por: Wong, Chi Wah, et al.
Publicado: (2020)

Radiogenomics in Colorectal Cancer
por: Badic, Bogdan, et al.
Publicado: (2021)

Radical penectomy, a compromise for life: results from the PECAD study
por: Ghahhari, Jamil, et al.
Publicado: (2020)

Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g8g65opggcsdtc1o3kgtaantcf